Abstract
The purpose of this chapter is to present an overview of current blood banking organizations and activities and the effect of the introduction of red cell substitutes. To do this job well, one would need to know the characteristics of each licensed red cell substitute, the sequence of licensure and their applications, costs, side effects, etc. One would also like to know what other new technologies will have been introduced at the time of the introduction of red cell substitutes. Of course, none of this information is available today and the range of possibilities is very broad. Therefore, any prediction of the impact of transfusion alternatives on blood banking must be considered less than precise. However, it is possible to focus on trends and principles to help the reader make predictions as s/he observes changes in the marketplace and as transfusion alternatives come closer to being a reality. To be inclusive, some circumstances that are not considered likely will be introduced and analyzed. This should prepare the reader a little better if today’s opinions turn out to be incorrect.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Braine, H. Professor, Oncology and Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD, Personal Communication, 1994.
Brand, A.. Passenger leukocytes cytokines, and transfusion reactions.N. Eng. J. Med.331: 670–671, 1994.
Busch, M. Scientific Director, Irwin Memorial Blood Center, San Francisco, CA. Remarks at the FDA Conference,The Feasibility of Genetic Technology to Close the HIV Window in Donor Screening, Silver Spring, MD, September 26, 1994.
Chassaigne, M. Directeur, Centre Regional de Transfusion Sanguine, Tours, 2, Boulevard Tonnelle (CHRU) BP 2009 37020 Tours, Personal Communication, 1994.
Dodd, R. Head, Transmissible Disease Department, Holland Laboratory, American Red Cross Biomedical Services, Remarks at the FDA Conference,The Feasibility of Genetic Technology to Close the HIV Window in Donor Screening, Silver Spring, MD, September 26, 1994.
Durbin, M., Bone marrow transplantation: economic, ethical and social issues.Pediatrics, 82: 774–783, 1988.
Emmanuel, J., Acting Chief, Global Blood Safety Unit, World Health Organization, Geneva Switzerland, Personal Communication, 1994.
European Union Directive 89/381/EEC
Kessler, D. Commissioner, U.S. Food and Drug Administration, Remarks to the FDA Conference, The Feasibility of Genetic Technology to Close the HIV Window in Donor Screening, Silver Spring, MD, September 26, 1994.
Quesenberry, P.J., H. Ramshaw, S. Peters, S. Rao, C. Tiarks, P. Lowry, M. Stewart, P. Becker, P. Newburger, and G. Stein. Normal hemopoiesis. In Blood Supply:Risks, Perceptions, and Prospects for the Future( S.T. Nance, ed.), Bethesda: American Association of Blood Banks, 1994.
van Aken, W.G., Director, Central Laboratory of the Netherlands, Red Cross Blood Transfusion Service, Amsterdam, The Netherlands, Personal Communication, 1994.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1995 Birkhäuser Boston
About this chapter
Cite this chapter
Tomasulo, P. (1995). Transfusion Alternatives: Impact on Blood Banking Worldwide. In: Winslow, R.M., Vandegriff, K.D., Intaglietta, M. (eds) Blood Substitutes. Birkhäuser Boston. https://doi.org/10.1007/978-1-4612-2576-8_1
Download citation
DOI: https://doi.org/10.1007/978-1-4612-2576-8_1
Publisher Name: Birkhäuser Boston
Print ISBN: 978-1-4612-7587-9
Online ISBN: 978-1-4612-2576-8
eBook Packages: Springer Book Archive